 Todd Bull
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 42 | 2023 | 1752 | 4.190 |
Why?
| | Scleroderma, Systemic | 6 | 2019 | 97 | 1.820 |
Why?
| | Pulmonary Embolism | 5 | 2022 | 182 | 1.380 |
Why?
| | Ventricular Dysfunction, Right | 7 | 2023 | 224 | 1.330 |
Why?
| | Vena Cava Filters | 2 | 2020 | 50 | 0.870 |
Why?
| | Thrombolytic Therapy | 3 | 2021 | 118 | 0.820 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 61 | 0.740 |
Why?
| | Airway Obstruction | 1 | 2021 | 170 | 0.680 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 233 | 0.650 |
Why?
| | Familial Primary Pulmonary Hypertension | 12 | 2023 | 190 | 0.650 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2020 | 243 | 0.630 |
Why?
| | Thrombosis | 4 | 2023 | 302 | 0.630 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 754 | 0.610 |
Why?
| | Epoprostenol | 4 | 2012 | 132 | 0.580 |
Why?
| | Growth Differentiation Factor 15 | 3 | 2013 | 34 | 0.570 |
Why?
| | Vascular Resistance | 5 | 2021 | 338 | 0.560 |
Why?
| | Endovascular Procedures | 1 | 2020 | 276 | 0.550 |
Why?
| | Herpesviridae Infections | 3 | 2008 | 138 | 0.540 |
Why?
| | Antihypertensive Agents | 2 | 2012 | 430 | 0.530 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 123 | 0.520 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 1115 | 0.520 |
Why?
| | Exercise Test | 3 | 2023 | 541 | 0.510 |
Why?
| | Altitude Sickness | 1 | 2017 | 152 | 0.510 |
Why?
| | Pulmonary Artery | 9 | 2023 | 1032 | 0.480 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 721 | 0.480 |
Why?
| | Echocardiography | 2 | 2020 | 566 | 0.470 |
Why?
| | Vasodilator Agents | 4 | 2023 | 308 | 0.470 |
Why?
| | Humans | 65 | 2023 | 115890 | 0.460 |
Why?
| | Altitude | 1 | 2017 | 410 | 0.430 |
Why?
| | Perioperative Care | 1 | 2014 | 127 | 0.430 |
Why?
| | Anticoagulants | 5 | 2023 | 545 | 0.430 |
Why?
| | Hypoxia | 5 | 2023 | 937 | 0.420 |
Why?
| | Endothelial Cells | 5 | 2011 | 694 | 0.410 |
Why?
| | Sulfones | 1 | 2012 | 98 | 0.390 |
Why?
| | Blood Cells | 1 | 2010 | 39 | 0.370 |
Why?
| | Venous Thromboembolism | 3 | 2021 | 234 | 0.370 |
Why?
| | Herpesvirus 8, Human | 3 | 2008 | 63 | 0.350 |
Why?
| | Hypertension, Portal | 2 | 2020 | 62 | 0.350 |
Why?
| | Piperazines | 1 | 2012 | 313 | 0.350 |
Why?
| | Oxygen Consumption | 1 | 2012 | 572 | 0.340 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 283 | 0.330 |
Why?
| | End Stage Liver Disease | 2 | 2020 | 74 | 0.330 |
Why?
| | Blood Coagulation | 2 | 2021 | 221 | 0.330 |
Why?
| | Virus Diseases | 1 | 2011 | 200 | 0.320 |
Why?
| | Lung | 8 | 2022 | 3685 | 0.300 |
Why?
| | Time Factors | 2 | 2017 | 6186 | 0.290 |
Why?
| | Acute Lung Injury | 1 | 2010 | 302 | 0.280 |
Why?
| | Blood Vessels | 1 | 2008 | 181 | 0.280 |
Why?
| | Middle Aged | 18 | 2022 | 27080 | 0.270 |
Why?
| | Respiratory Function Tests | 1 | 2007 | 541 | 0.260 |
Why?
| | Ventricular Function, Right | 4 | 2023 | 251 | 0.260 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2005 | 8 | 0.260 |
Why?
| | Microarray Analysis | 1 | 2005 | 120 | 0.260 |
Why?
| | Male | 25 | 2022 | 56123 | 0.260 |
Why?
| | Cardiac Catheterization | 5 | 2023 | 535 | 0.240 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2007 | 418 | 0.240 |
Why?
| | Female | 24 | 2022 | 60076 | 0.240 |
Why?
| | Castleman Disease | 1 | 2003 | 13 | 0.230 |
Why?
| | Heart Ventricles | 4 | 2023 | 712 | 0.230 |
Why?
| | Pulmonary Emphysema | 2 | 2007 | 318 | 0.230 |
Why?
| | Gene Expression Profiling | 2 | 2007 | 1547 | 0.210 |
Why?
| | Heparin | 2 | 2021 | 226 | 0.210 |
Why?
| | Vascular Neoplasms | 1 | 2022 | 16 | 0.200 |
Why?
| | Biopsy | 1 | 2005 | 1056 | 0.200 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 16 | 0.200 |
Why?
| | Embolectomy | 1 | 2020 | 10 | 0.180 |
Why?
| | Aromatase | 1 | 2020 | 31 | 0.180 |
Why?
| | Growth Differentiation Factor 2 | 1 | 2020 | 2 | 0.180 |
Why?
| | Thrombectomy | 1 | 2020 | 53 | 0.180 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2020 | 25 | 0.180 |
Why?
| | Pulmonary Circulation | 4 | 2023 | 408 | 0.180 |
Why?
| | Tuberculosis | 1 | 2003 | 243 | 0.180 |
Why?
| | Forced Expiratory Volume | 1 | 2021 | 522 | 0.180 |
Why?
| | Drug Resistance | 1 | 2020 | 162 | 0.170 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2020 | 133 | 0.170 |
Why?
| | Endothelium, Vascular | 5 | 2007 | 845 | 0.170 |
Why?
| | Risk Factors | 7 | 2018 | 8714 | 0.170 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 228 | 0.170 |
Why?
| | Vascular Stiffness | 1 | 2023 | 411 | 0.160 |
Why?
| | Critical Illness | 2 | 2021 | 646 | 0.160 |
Why?
| | Polymerase Chain Reaction | 3 | 2008 | 1001 | 0.160 |
Why?
| | Aged | 10 | 2021 | 19296 | 0.160 |
Why?
| | Sildenafil Citrate | 2 | 2023 | 58 | 0.160 |
Why?
| | Hemodynamics | 2 | 2014 | 970 | 0.150 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 292 | 0.150 |
Why?
| | Estrogens | 1 | 2020 | 316 | 0.150 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2018 | 63 | 0.150 |
Why?
| | Acute Disease | 1 | 2020 | 917 | 0.150 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 19 | 0.150 |
Why?
| | Schistosoma | 1 | 2017 | 18 | 0.150 |
Why?
| | Purines | 2 | 2023 | 159 | 0.150 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.150 |
Why?
| | Transforming Growth Factor beta | 2 | 2017 | 447 | 0.140 |
Why?
| | Risk Assessment | 3 | 2023 | 3004 | 0.140 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2021 | 99 | 0.140 |
Why?
| | Adult | 14 | 2023 | 30814 | 0.140 |
Why?
| | Pandemics | 2 | 2021 | 1333 | 0.140 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2016 | 37 | 0.140 |
Why?
| | Bone Marrow Cells | 1 | 2017 | 272 | 0.130 |
Why?
| | Retrospective Studies | 8 | 2023 | 12616 | 0.130 |
Why?
| | Intensive Care Units | 1 | 2020 | 616 | 0.130 |
Why?
| | Patient Care Team | 1 | 2020 | 521 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2013 | 945 | 0.130 |
Why?
| | Systole | 1 | 2016 | 168 | 0.130 |
Why?
| | Cohort Studies | 3 | 2017 | 4961 | 0.130 |
Why?
| | Prognosis | 3 | 2013 | 3342 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 343 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 335 | 0.130 |
Why?
| | Health Surveys | 1 | 2017 | 449 | 0.120 |
Why?
| | Blood Pressure | 2 | 2016 | 1536 | 0.120 |
Why?
| | Myocardial Contraction | 1 | 2016 | 316 | 0.120 |
Why?
| | Exercise | 3 | 2022 | 1610 | 0.120 |
Why?
| | ROC Curve | 1 | 2016 | 451 | 0.120 |
Why?
| | Heart Failure | 2 | 2020 | 1959 | 0.120 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2011 | 82 | 0.120 |
Why?
| | Lung Diseases, Interstitial | 2 | 2013 | 520 | 0.120 |
Why?
| | Anesthetics | 1 | 2014 | 57 | 0.120 |
Why?
| | Heart-Assist Devices | 1 | 2020 | 486 | 0.110 |
Why?
| | Positive-Pressure Respiration | 1 | 2014 | 67 | 0.110 |
Why?
| | Precision Medicine | 1 | 2017 | 356 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4446 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 2 | 2007 | 503 | 0.110 |
Why?
| | Respiratory System Agents | 1 | 2013 | 22 | 0.110 |
Why?
| | Drug Discovery | 1 | 2013 | 124 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1403 | 0.110 |
Why?
| | Phenotype | 3 | 2010 | 2858 | 0.110 |
Why?
| | Drug Storage | 1 | 2012 | 58 | 0.100 |
Why?
| | Drug Stability | 1 | 2012 | 152 | 0.100 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2011 | 24 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2010 | 2814 | 0.100 |
Why?
| | Drug Approval | 1 | 2012 | 78 | 0.100 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2011 | 10 | 0.100 |
Why?
| | Case-Control Studies | 4 | 2020 | 3056 | 0.100 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2011 | 29 | 0.100 |
Why?
| | Troponin | 1 | 2011 | 45 | 0.100 |
Why?
| | Europe | 1 | 2012 | 352 | 0.100 |
Why?
| | Blood Gas Analysis | 1 | 2011 | 69 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3086 | 0.100 |
Why?
| | Antithrombins | 1 | 2011 | 48 | 0.100 |
Why?
| | Hyponatremia | 1 | 2011 | 37 | 0.100 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 64 | 0.100 |
Why?
| | Medical History Taking | 1 | 2011 | 115 | 0.100 |
Why?
| | Ultrasonography | 2 | 2011 | 671 | 0.090 |
Why?
| | Receptors, Interleukin-7 | 1 | 2010 | 26 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2021 | 9165 | 0.090 |
Why?
| | Registries | 3 | 2022 | 1773 | 0.090 |
Why?
| | Predictive Value of Tests | 4 | 2023 | 1817 | 0.090 |
Why?
| | Mutation, Missense | 1 | 2011 | 296 | 0.090 |
Why?
| | Demography | 1 | 2010 | 264 | 0.090 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 301 | 0.090 |
Why?
| | Prospective Studies | 4 | 2022 | 6266 | 0.080 |
Why?
| | Aldosterone | 1 | 2009 | 42 | 0.080 |
Why?
| | Cluster Analysis | 1 | 2010 | 466 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2207 | 0.080 |
Why?
| | Vasopressins | 1 | 2009 | 57 | 0.080 |
Why?
| | Caspase 7 | 1 | 2008 | 22 | 0.080 |
Why?
| | Vasoconstrictor Agents | 1 | 2009 | 113 | 0.080 |
Why?
| | Bone Morphogenetic Protein 4 | 1 | 2008 | 34 | 0.080 |
Why?
| | Electrocardiography | 1 | 2011 | 554 | 0.080 |
Why?
| | United States | 4 | 2022 | 12340 | 0.080 |
Why?
| | In Situ Nick-End Labeling | 1 | 2008 | 119 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 934 | 0.080 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 105 | 0.080 |
Why?
| | Research Design | 1 | 2013 | 947 | 0.080 |
Why?
| | Animals | 9 | 2017 | 32120 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 399 | 0.070 |
Why?
| | Caspase 3 | 1 | 2008 | 237 | 0.070 |
Why?
| | Colorado | 1 | 2017 | 4122 | 0.070 |
Why?
| | Acrolein | 1 | 2007 | 23 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2010 | 1058 | 0.070 |
Why?
| | Survival Analysis | 1 | 2010 | 1221 | 0.070 |
Why?
| | Quality of Life | 3 | 2022 | 2391 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1444 | 0.070 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2007 | 142 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 794 | 0.070 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2005 | 56 | 0.070 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2005 | 24 | 0.070 |
Why?
| | Pleural Diseases | 1 | 2005 | 21 | 0.060 |
Why?
| | Comorbidity | 1 | 2010 | 1476 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2005 | 108 | 0.060 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2005 | 82 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 965 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 3916 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2008 | 679 | 0.060 |
Why?
| | Adolescent | 4 | 2021 | 17949 | 0.060 |
Why?
| | Biomarkers | 4 | 2013 | 3473 | 0.060 |
Why?
| | Algorithms | 1 | 2011 | 1493 | 0.060 |
Why?
| | Vasodilation | 3 | 2010 | 413 | 0.060 |
Why?
| | Carrier Proteins | 1 | 2008 | 703 | 0.060 |
Why?
| | Cattle | 2 | 2017 | 935 | 0.060 |
Why?
| | Apoptosis | 3 | 2008 | 2377 | 0.060 |
Why?
| | Blood Circulation | 1 | 2003 | 35 | 0.060 |
Why?
| | CD36 Antigens | 1 | 2003 | 38 | 0.060 |
Why?
| | Forecasting | 1 | 2005 | 332 | 0.060 |
Why?
| | E-Selectin | 1 | 2003 | 53 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 526 | 0.060 |
Why?
| | Blood Donors | 1 | 2004 | 89 | 0.060 |
Why?
| | Veins | 1 | 2003 | 57 | 0.060 |
Why?
| | Blood | 1 | 2003 | 97 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2016 | 3583 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2003 | 273 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 376 | 0.050 |
Why?
| | Drainage | 1 | 2003 | 151 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 961 | 0.050 |
Why?
| | Receptors, Growth Factor | 1 | 2002 | 49 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 50 | 0.050 |
Why?
| | Lymphokines | 1 | 2002 | 115 | 0.050 |
Why?
| | Vascular Diseases | 1 | 2005 | 230 | 0.050 |
Why?
| | Partial Thromboplastin Time | 1 | 2021 | 51 | 0.050 |
Why?
| | Rivaroxaban | 1 | 2023 | 210 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 4449 | 0.050 |
Why?
| | Vascular Remodeling | 1 | 2023 | 148 | 0.050 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 198 | 0.050 |
Why?
| | Proteomics | 2 | 2022 | 854 | 0.050 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1129 | 0.050 |
Why?
| | Cytochrome P-450 CYP1B1 | 1 | 2020 | 5 | 0.050 |
Why?
| | Brachial Artery | 2 | 1999 | 174 | 0.050 |
Why?
| | Catheters | 1 | 2021 | 64 | 0.050 |
Why?
| | Lymph Nodes | 1 | 2003 | 422 | 0.050 |
Why?
| | Mass Screening | 1 | 2007 | 1023 | 0.050 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 57 | 0.050 |
Why?
| | United Kingdom | 1 | 2021 | 232 | 0.050 |
Why?
| | Liver Function Tests | 1 | 2020 | 105 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2022 | 138 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2002 | 225 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 327 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2020 | 120 | 0.040 |
Why?
| | Smoking | 1 | 2007 | 1468 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1643 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 184 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 1088 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2362 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 616 | 0.040 |
Why?
| | Enalapril | 1 | 1998 | 16 | 0.040 |
Why?
| | Survival Rate | 1 | 2022 | 1653 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 296 | 0.040 |
Why?
| | Antigens, Ly | 1 | 2017 | 45 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 180 | 0.040 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 2 | 2010 | 48 | 0.040 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 101 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2021 | 675 | 0.040 |
Why?
| | Education | 1 | 2017 | 99 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 682 | 0.030 |
Why?
| | Th2 Cells | 1 | 2017 | 162 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 4525 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2023 | 2196 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 226 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 504 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 440 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 1761 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2016 | 779 | 0.030 |
Why?
| | Mice | 2 | 2007 | 15073 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 8 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2408 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 678 | 0.030 |
Why?
| | Perioperative Period | 1 | 2012 | 49 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2022 | 0.030 |
Why?
| | Liver Transplantation | 1 | 2020 | 830 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2013 | 120 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2018 | 6437 | 0.030 |
Why?
| | Sp1 Transcription Factor | 1 | 2011 | 23 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2011 | 52 | 0.030 |
Why?
| | International Cooperation | 1 | 2012 | 175 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 2011 | 121 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2503 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2011 | 219 | 0.020 |
Why?
| | Introns | 1 | 2011 | 228 | 0.020 |
Why?
| | Anesthesia | 1 | 2012 | 119 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2013 | 245 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2011 | 165 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2011 | 141 | 0.020 |
Why?
| | Physical Examination | 1 | 2012 | 224 | 0.020 |
Why?
| | RNA Splicing | 1 | 2011 | 244 | 0.020 |
Why?
| | Leg | 1 | 2011 | 227 | 0.020 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 235 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2017 | 2581 | 0.020 |
Why?
| | Spironolactone | 1 | 2009 | 33 | 0.020 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2009 | 44 | 0.020 |
Why?
| | Contrast Media | 1 | 2011 | 366 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1183 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 632 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2009 | 155 | 0.020 |
Why?
| | Endothelin-1 | 1 | 2010 | 167 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 4767 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 10515 | 0.020 |
Why?
| | Protein Binding | 1 | 2011 | 1919 | 0.020 |
Why?
| | Research | 1 | 2009 | 398 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1319 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2010 | 834 | 0.020 |
Why?
| | Gene Expression | 1 | 2010 | 1442 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 346 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1374 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 304 | 0.010 |
Why?
| | Mutation | 2 | 2005 | 3369 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1530 | 0.010 |
Why?
| | Genes, Viral | 1 | 2003 | 89 | 0.010 |
Why?
| | Cyclins | 1 | 2003 | 79 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2424 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 61 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1998 | 3258 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2167 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 104 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2005 | 356 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 1970 | 0.010 |
Why?
| | DNA, Viral | 1 | 2003 | 351 | 0.010 |
Why?
| | Viral Proteins | 1 | 2003 | 283 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 407 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 4670 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2003 | 733 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 5555 | 0.010 |
Why?
| | Ultrasonography, Doppler, Pulsed | 1 | 1999 | 6 | 0.010 |
Why?
| | Administration, Sublingual | 1 | 1999 | 13 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2002 | 504 | 0.010 |
Why?
| | Nitroglycerin | 1 | 1999 | 22 | 0.010 |
Why?
| | Lipoprotein(a) | 1 | 1999 | 51 | 0.010 |
Why?
| | Video Recording | 1 | 1999 | 147 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 1999 | 185 | 0.010 |
Why?
| | Fibrinogen | 1 | 1999 | 160 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 1998 | 83 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 324 | 0.010 |
Why?
| | Reference Values | 1 | 1999 | 745 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 1998 | 243 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 961 | 0.010 |
Why?
| | Double-Blind Method | 1 | 1998 | 1665 | 0.010 |
Why?
| | Military Personnel | 1 | 1999 | 526 | 0.010 |
Why?
|
|
Bull's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|